HONG KONG – Japan's Chugai Pharmaceutical Co. Ltd. has licensed rights to its treatment for skin diseases to the company's Swiss partner, Galderma Pharma SA. The global agreement gives Lausanne-based Galderma rights to antibody nemolizumab, or CIM331. The drug is close to completing a global phase II study in the U.S., Japan and three European countries, for the treatment of atopic dermatitis.